Transient exposure to PTHrP (107-139) exerts anabolic effects through vascular endothelial growth factor receptor 2 in human osteoblastic cells in vitro

Calcified Tissue International

Volumn 79, Issue 5, 2006, Pages 360-369

  De Gortazar A R ^a   Alonso, V ^a   Alvarez Arroyo, M V ^a   Esbrit, P ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

C terminal parathyroid hormone related protein; Human osteoblastic cell; Osteoblast differentiation; Vascular endothelial growth factor receptor 2

Indexed keywords

ALKALINE PHOSPHATASE; ANTIBODY; ASPARAGINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUCINE; MESSENGER RNA; OSTEOCALCIN; OSTEOPROTEGERIN; PARATHYROID HORMONE RELATED PROTEIN; PROTEIN DERIVATIVE; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RUNT HOMOLOGY DOMAIN PROTEIN; SOMATOMEDIN A; TRYPTOPHAN; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CELL DIFFERENTIATION; CELL LINE; CELL METABOLISM; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION;

ALKALINE PHOSPHATASE; CELL LINE; CORE BINDING FACTOR ALPHA 1 SUBUNIT; HUMANS; OSTEOBLASTS; OSTEOCALCIN; PARATHYROID HORMONE-RELATED PROTEIN; PEPTIDE FRAGMENTS; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 33845448556     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-006-0099-y     Document Type: Article

References (45)

1. Strewler GJ (2000) The physiology of parathyroid hormone-related protein. N Engl J Med 342:177-185
2. Karaplis AC, Luz A, Glowacki J, Bronson RT, Tybulewicz VLJ, Kronenberg HM, Mulligan RC (1994) Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes Dev 8:277-289
3. Lanske B, Karaplis AC, Lee K, Luz A, Vortkamp A, Pirro A, Karperien M, Defize L, Ho C, Mulligan RC, Abou Samra AB, Jüppner H, Segre GV, Kronenberg HM (1996) PTH/PTHrP receptor in early development and Indian Hedgehog-regulated bone growth. Science 273:663-666
4. Kartsogiannis V, Moseley J, McKelvie B, Chou ST, Hards DK, Ng KW, Martin TJ, Zhou H (1997) Temporal expression of PTHrP during endochondral bone formation in mouse and intramembranous bone formation in an in vivo rabbit model. Bone 21:385-392
5. Lomri A, de Pollak C, Sebag M, Goltzman D, Kremer R, Marie PJ (1997) Expression of parathyroid hormone-related peptide (PTHrP) and PTH/PTHrP receptor in newborn human calvaria osteoblastic cells. Eur J Endocrinol 136:640-648
6. McCauley LK, Koh AJ, Beecher CA, Cui Y, Rosol TJ, Franceschi RT (1996) PTH/PTHrP receptor is temporally regulated during osteoblast differentiation and is associated with collagen synthesis. J Cell Biochem 61:638-647
7. Martínez P, Esbrit P, Rodrigo A, Alvarez-Arroyo MV, Martínez ME (2002) Age-related changes in parathyroid hormone-related protein and vascular endothelial growth factor in human osteoblastic cells. Osteoporosis Int 13:874-881
8. Carpio L, Gladu J, Goltzman D, Rabbani SA (2001) Induction of osteoblast differentiation indexes by PTHrP in MG-63 cells involves multiple signaling pathways. Am J Physiol Endocrinol Metab 281:E489-E499
9. Miao D, Tong X-K, Chan GK, Panda D, McPherson PS, Goltzman D (2001) Parathyroid hormone-related peptide stimulates osteogenic cell proliferation through protein kinase C activation of the ras/mitogen-activated protein kinase signaling pathway. J Biol Chem 276:32204-32213
10. Martínez ME, García-Ocaña A, Sánchez M, Medina S, del Campo T, Valín A, Sánchez-Cabezudo MJ, Esbrit P (1997) C-terminal parathyroid hormone-related protein inhibits proliferation and differentiation of human osteoblast-like cells. J Bone Miner Res 12:778-785
11. Valín A, García-Ocaña A, de Miguel F, Sarasa JL, Esbrit P (1997) Antiproliferative effect of the C-terminal fragments of parathyroid hormone-related protein, PTHrP (107-111) and (107-139), on osteoblastic osteosarcoma cells. J Cell Physiol 170:209-215
12. Valín A, de Miguel F, García-Ocaña A, Esbrit P (1998) Parathyroid hormone-related protein (107-139) decreases alkaline phosphatase in osteoblastic osteosarcoma cells UMR 106 by a protein kinase C-dependent pathway. Calcif Tissue Int 65:148-151
13. Stewart AF (2002) Hyperparathyroidism, humoral hypercalcemia of malignancy, and the anabolic actions of parathyroid hormone and parathyroid hormone-related protein on the skeleton. J Bone Miner Res 17:758-762
14. Horwitz MJ, Tedesco MB, Gundberg C, García-Ocaña A, Stewart AF (2003) Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88:569-575
15. Rouffet J, Coxam V, Gaumet N, Barlet JP (1994) Preserved bone mass in ovariectomized rats treated with parathyroid hormone-related peptide (1-34) and (107-111) fragments. Reprod Nutr Dev 34:473-481
16. Stewart AF, Cain RL, Burr DB, Jacob D, Turner CH, Hock JM (2000) Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893. J Bone Miner Res 15:1517-1525
17. Bikle DD, Sakata T, Leary C, Elalieh H, Ginzinger D, Rosen CJ, Beamer W, Majumdar S, Halloran BP (2002) Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res 17:1570-1578
18. Canalis E, McCarthy TL, Centrella M (1990) Differential effects of continuous and transient treatment with parathyroid hormone-related peptide (PTHrP) on bone collagen synthesis. Endocrinology 126:1806-1812
19. Cornish J, Callon KE, Nicholson GC, Reid IR (1997) Parathyroid hormone-related protein (107-139) inhibits bone resorption in vivo. Endocrinology 138:1299-1304
20. Fenton AJ, Kemp BE, Kent GN, Moseley JM, Zheng MH, Rowe DJ, Britto JM, Martin TJ, Nicholson GC (1991) A carboxyl-terminal peptide from the parathyroid hormone-related protein inhibits bone resorption by osteoclasts. Endocrinology 129:1762-1768
21. Miao D, Su H, He B, Gao J, Xia Q, Goltzman D, Karaplis AC (2005) Deletion of the mid- and carboxyl regions of PTHrP produces growth retardation and early senescence in mice [abstract]. J Bone Miner Res 20(suppl 1):S14
22. Cornish J, Callon KE, Lin C, Xiao C, Moseley JM, Reid IR (1999) Stimulation of osteoblast proliferation by C-terminal fragments of parathyroid hormone-related protein. J Bone Miner Res 14:915-922
23. 2+ through a receptor different from the type 1 PTH/PTHrP receptor in osteoblastic osteosarcoma UMR 106 cells. Endocrinology 142:2752-2759
24. Brandi ML, Collin-Osdoby P (2006) Vascular biology and the skeleton. J Bone Miner Res 21:183-192
25. Esbrit P, Alvarez-Arroyo MV, de Miguel F, Martín O, Martínez ME, Caramelo C (2000) C-terminal parathyroid hormone-related protein increases vascular endothelial growth factor in human osteoblastic cells. J Am Soc Nephrol 11:1085-1092
26. Ishizuya T, Yokose S, Hori M, Noda T, Suda T, Yoshiki S, Yamaguchi A (1997) Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest 99:2961-2970
27. Locklin RM, Khosla S, Turner RT, Riggs BL (2003) Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem 89:180-190
28. Schiller PC, D'ippolito G, Roos BA, Howard GA (1999) Anabolic or catabolic responses of MC3T3-E1 osteoblastic cells to parathyroid hormone depend on time and duration of treatment. J Bone Miner Res 14:1504-1512
29. Bilbe G, Roberts E, Birch M, Evans DB (1996) PCR phenotyping of cytokines, growth factors and their receptors and bone matrix proteins in human osteoblast-like cell lines. Bone 19:437-445
30. Guillén C, Martínez P, de Gortázar AR, Martínez ME, Esbrit P (2002) Both N- and C-terminal domains of parathyroid hormone-related protein increase interleukin-6 y NF-κB activation in osteoblastic cells. J Biol Chem 277:28109-28117
31. 3 stimulation and basal VDR expression in human osteoblastic cells according to donor age and skeletal origin. Bone 29:35-41
32. Alvarez-Arroyo MV, Yagüe S, Wenger RM, Rich DH, Jiménez S, González-Pacheco FR, Castilla MA, Deudero JJP, Caramelo C (2002) Cyclophilin mediated pathways in the effect of cyclosporin A on endothelial cells: role of vascular growth factor. Circ Res 91:202-209
33. Komori T, Kishimoto T (1998) Cbfa1 in bone development. Curr Opin Genet Dev 8:494-499
34. Abou-Samra A-B, Jüppner H, Force T, Freeman MW, Kong X-F, Schipani E, Ureña P, Richards J, Bonventre JV, Potts JT Jr, Kronenberg HM, Segre GV (1992) Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide for rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Proc Natl Acad Sci USA 89:2732-2736
35. Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, Riggs BL (2000) The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 141:4768-4776
36. Thomas GP, Baker SUK, Eisman JA, Gardiner EM (2001) Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. J Endocrinol 170:451-460
37. Nutt RF, Caulfield MP, Levy JJ, Gibbons SW, Rosenblatt M, McKee RL (1990) Removal of partial agonism from parathyroid hormone (PTH)-related protein-(7-34)NH2 by substitution of PTH amino acids at positions 10 and 11. Endocrinology 127:491-493
38. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N (1999) VEGF couples hypertrophy cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5:623-628
39. 3 in human osteoblast-like cells. J Bone Miner Res 11:472-479
40. Mandelin J, Li TF, Liljestrom M, Kroon ME, Hanemaaijer R, Santavirta S, Konttinen YT (2003) Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. J Bone Joint Surg Br 85:1196-1201
41. Deckers MML, Karperien M, van der Bent C, Yamashita T, Papapoulos SE, Löwik CWGM (2000) Expression of vascular endothelial growth factor and their receptors during osteoblast differentiation. Endocrinology 141:1667-1674
42. Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF, Zaidi M (2003) TSH is a negative regulator of skeletal remodeling. Cell 115:151-162
43. Hiltunen MO, Ruuskanen M, Huuskonen J, Mahonen AJ, Ahonen M, Rutanen J, Kosma VM, Mahonen A, Kroger H, Yla-Herttuala S (2003) Adenovirus-mediated VEGF-A gene transfer induces bone formation in vivo. FASEB J 17:1147-1149
44. Yang X, Hallday D, Onyia JE, Martin TJ, Chandrasekhar S (2002) Protein kinase C is a mediator of the synthesis and secretion of osteoprotegerin in osteoblast-like cells. Biochem Biophys Res Commun 290:42-46
45. Yagüe S, Caramelo C, Berruguete R, Alvarez-Arroyo MV (2004) PI3-K/AKT and reactive oxygen species (ROS) signaling pathways are implicated in the regulation of the receptor 2 of vascular endothelial growth factor (VEG-FR2) by cyclosporin A (CsA) [abstract]. J Am Soc Nephrol 15:407A